News

Intercell has reported that interim data from a phase II clinical trial investigating the vaccine candidate for the prevention of infections with the bacterium pseudomonas aeruginosa are available.

ChemoCentryx has initiated patient enrollment in a Phase 2 clinical trial of CCX354, an orally-bioavailable, small molecule drug, designed to specifically target the CCR1 chemokine receptor for the

BioSpecifics Technologies has reported top-line efficacy and safety results from a Phase 2b clinical trial of Xiaflex for the treatment of peyronie’s disease. The Phase 2b study, conducted

Hospira and Orchid Chemicals & Pharmaceuticals have announced an agreement for Hospira to acquire Orchid’s generic injectable finished-dosage form pharmaceuticals business for approximately $400m. The acquisition includes Orchid’s

Almac Discovery (Almac) has initiated Phase I clinical trial of the intranasal Granisetron product. The product, which uses Archimedes’ proprietary ChiSys delivery technology, is being developed as a

Array BioPharma (Array) and Amgen have entered into an agreement. The deal grants Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested

Lytix Biopharma has announced approvals from the Norwegian Medicines Agency (Statens legemiddelverk) and the Swedish Medical Products Agency (Lakemedelverket) to commence Phase I clinical trials of Oncopore (LTX-315)

Femta Pharmaceuticals (Femta) and Lonza have entered into a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a monoclonal antibody in late

Gilead Sciences (Gilead) has reported that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan did not achieve its co-primary efficacy endpoints of change from baseline to week